MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
18.29
+0.06 (0.33%)
May 27, 2026, 11:40 AM EDT - Market open
MLTX Stock Forecast
Stock Price Forecast
According to 15 analysts polled by S&P Global, MLTX stock has a consensus rating of "Buy" and an average price target of $27.62. The average 1-year stock price forecast is 51.01% higher than the current stock price, while the lowest is $6.00 (-67.20%) and the highest is $46 (+151.50%).
Price Target: $27.62 (+51.01%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for MLTX stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 11 | 11 | 10 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 6 | 4 | 3 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 2 | 3 | 3 | 2 | 2 | 2 |
| Total | 17 | 17 | 16 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Maintains $33 | Buy | Maintains | $33 | +80.43% | May 19, 2026 |
| Needham | Needham | Buy Reiterates $30 | Buy | Reiterates | $30 | +64.02% | May 12, 2026 |
| BTIG | BTIG | Buy Reiterates $30 | Buy | Reiterates | $30 | +64.02% | May 12, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $13 → $16 | Hold | Maintains | $13 → $16 | -12.52% | May 12, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 11, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
21.28M
EPS This Year
-3.89
from -3.53
EPS Next Year
-3.72
from -3.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 43.6M | ||||||
| Avg | n/a | 21.3M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.00 | -3.05 | ||||||
| Avg | -3.89 | -3.72 | ||||||
| Low | -5.06 | -4.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.